Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / LCP2

LCP2

Basics

Aliases:
This biomarker is also known as:
  • SLP76,
  • SH2 domain-containing leukocyte protein of 76kD,
  • lymphocyte cytosolic protein 2 (SH2 domain-containing leukocyte protein of 76kD),
  • lymphocyte cytosolic protein 2,
  • SLP-76,
  • lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa),
  • SLP-76 tyrosine phosphoprotein,
  • SH2 domain-containing leukocyte protein of 76 kDa,
  • 76 kDa tyrosine phosphoprotein,

View in BioMuta

Description…

LCP2, previously known as SLP76, functions as an adaptor or scaffolding protein. LCP2 has three modular domains. The amino-terminal end has an acidic region that includes a PEST domain and several tyrosine residues which are phosphorylated following TCR ligation. LCP2 also contains a central proline-rich domain and a COOH-terminal SH2 domain.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

No additional breast data is available.

Performance Comment

LCP2 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html